Treatment with Lutetium-prostate-specific membrane antigen (PSMA) has shown survival benefit in patients with metastatic castration-resistant PSMA-positive prostate cancer who have previously received newer antihormonal treatment and chemotherapy [42]. This evidence concerns the gene FOLH1 and prostate cancer.